Vimarsana
Biggest News Aggregation in the World

Page 9 - Peter Altman News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Peter Altman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Peter Altman Today - Breaking & Trending Today

First New Port Richey public hearing for millage rate set for September - Vimarsana News

First New Port Richey public hearing for millage rate set for September

NEW PORT RICHEY — The City Council has approved a tentative millage rate of 8.5 for fiscal year 2022-23, the same rate as last year.

BIOCARDIA : REPORTS SECOND QUARTER 2022 BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS - Form 8-K - Vimarsana News

BIOCARDIA : REPORTS SECOND QUARTER 2022 BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS - Form 8-K

BIOCARDIA REPORTS SECOND QUARTER 2022 BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS Sunnyvale, Calif. - August 10, 2022 -BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and... | August 10, 2022

BioCardia to Participate in Upcoming Heart and Pulmonary Therapy Development Symposia - Vimarsana News

BioCardia to Participate in Upcoming Heart and Pulmonary Therapy Development Symposia

12.07.2022 - SUNNYVALE, Calif., July 12, 2022 (GLOBE NEWSWIRE) - BioCardia, Inc. [Nasdaq: BCDA], Sunnyvale, Calif. – BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary ...

BioCardia, Inc. (BCDA) CEO Peter Altman on Q1 2022 Results - Earnings Call Transcript - Vimarsana News

BioCardia, Inc. (BCDA) CEO Peter Altman on Q1 2022 Results - Earnings Call Transcript

BioCardia, Inc. (NASDAQ:NASDAQ:BCDA) Q1 2022 Earnings Conference Call May 11, 2022 04:30 PM ET Company Participants Jules Abraham - Investor Relations, CORE IR Peter Altman - President...

Follow the Insiders and Buy the Dip in These 3 Stocks - Vimarsana News

Follow the Insiders and Buy the Dip in These 3 Stocks

These three biotech companies have all had insiders buying shares recently. That's a good sign for the future of their treatments.